Date: 2016-02-16
Type of information: Licensing agreement
Compound: cellular immunotherapies targeting the inhibition of Cbl-b in T cells
Company: Apeiron Biologics (Austria) Columbia University (USA - NY)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: cell immunotherapy.
Disease:
Details: * On February 16, 2016, Apeiron Biologics announced that it has entered into an exclusive license agreement with Columbia University through their technology transfer office, Columbia Technology Ventures. Under the terms of the agreement, Apeiron obtains worldwide exclusive rights to develop and commercialize active cellular immunotherapies under the licensed patents, which cover the inhibition of Cbl-b in T cells for the treatment of cancer. Inhibition of Cbl-b is a new strategy for checkpoint blockade, designed to activate the immune system against cancer. Apeiron is already developing APN401, an individual adoptive cell therapy in which human peripheral blood mononuclear cells are silenced ex-vivo for Cbl-b (an E3 ubiquitin ligase) using small interfering ribonucleic acid (siRNA), and ubsequently re-administered to the patient, with the entire procedure taking place on the bedside in one day, avoiding any additional handling and shipment. A phase I clinical trial studying safety, tolerability and optimal dose of APN401 is ongoing at the Wake Forest Baptist Medical Center in North Carolina, USA.
Financial terms:
Latest news:
